Somehow he saw a small patient diagnosis for Cholangiocarcinoma and DLBLC and started to immediately downramp the commercial viable of IMU's IP. Yet he can't see there's a big question around the commercial viability and valuation for RC220 where the clinical trial is conducted in combination with another chemotherapy drug currently used as SoC despite bisantrene also being a 5 decades chemotherapy drug and they told me has better efficacy and safety but hasn't been preferred over another chemotherapy drug in doxorubicin for over 5 decades and more importantly no BP has even bother to advance bisantrene for over 5 decades is very telling.
IMU Price at posting:
4.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)